Symbiotec Pharmalab has successfully raised ₹2,180 crore through its initial public offering (IPO), underscoring robust investor confidence in its growth strategy and operational performance. The funds are earmarked for expanding manufacturing capacity, bolstering research and development, and pursuing strategic acquisitions to strengthen market presence. Analysts note that the oversubscribed IPO reflects strong demand for pharmaceutical equities amid rising domestic healthcare consumption and growing export opportunities.